K-BD Group (韩国 制药 and Bio Business Development Research Group, Chairman Lee Jae-hyeon) hosted a Promising Bio-Venture & 初创企业 Investment Forum on the 15th. Twenty companies with outstanding technological capabilities in areas such as rare disease new drugs, anticancer agents, drug delivery systems (DDS), and new drug target identification solutions participated to present their respective capabilities and 研发 管线s. The investment forum continued through the 16th at KINTEX in Ilsan.
Senior Managing Director Kim Seunghoon stated, "RCI001 has completed the 临床前 toxicology and DS (drug substance) stages, and a German company is scheduled to begin finished drug manufacturing next month," adding, "We anticipate entering Phase 1 临床试验 in the second half of this year, with the goal of entering FDA Phase 2 临床试验 in the first half of next year."
